CR20160369A - Composiciones para uso en el tratamiento de afecciones alérgicas - Google Patents
Composiciones para uso en el tratamiento de afecciones alérgicasInfo
- Publication number
- CR20160369A CR20160369A CR20160369A CR20160369A CR20160369A CR 20160369 A CR20160369 A CR 20160369A CR 20160369 A CR20160369 A CR 20160369A CR 20160369 A CR20160369 A CR 20160369A CR 20160369 A CR20160369 A CR 20160369A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compositions
- treatment
- allergic
- allergic affections
- affections
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000000172 allergic effect Effects 0.000 title 1
- 208000010668 atopic eczema Diseases 0.000 title 1
- 206010027654 Allergic conditions Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000013566 allergen Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Physiology (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
En la presente se proporcionan composiciones y métodos para el tratamiento de afecciones alérgicas, mediante la administración de una composición adyuvante con o sin alérgeno.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461929780P | 2014-01-21 | 2014-01-21 | |
PCT/US2015/012003 WO2015112485A1 (en) | 2014-01-21 | 2015-01-20 | Compositions for use in the treatment of allergic conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20160369A true CR20160369A (es) | 2016-10-05 |
Family
ID=52462439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20160369A CR20160369A (es) | 2014-01-21 | 2015-01-20 | Composiciones para uso en el tratamiento de afecciones alérgicas |
Country Status (19)
Country | Link |
---|---|
US (1) | US20160030459A1 (es) |
EP (1) | EP3096764A1 (es) |
JP (1) | JP2017502977A (es) |
KR (1) | KR20160105813A (es) |
CN (1) | CN105960241A (es) |
AU (1) | AU2015209575A1 (es) |
BR (1) | BR112016016672A2 (es) |
CA (1) | CA2935722A1 (es) |
CL (1) | CL2016001843A1 (es) |
CR (1) | CR20160369A (es) |
EA (1) | EA201691452A1 (es) |
HK (1) | HK1225994A1 (es) |
IL (1) | IL246587A0 (es) |
MA (1) | MA39228A1 (es) |
MX (1) | MX2016009464A (es) |
PH (1) | PH12016501434A1 (es) |
SG (1) | SG11201605883UA (es) |
TW (1) | TW201620524A (es) |
WO (1) | WO2015112485A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101858840B1 (ko) * | 2016-01-15 | 2018-05-16 | 단국대학교 천안캠퍼스 산학협력단 | 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제 |
EP3474013A4 (en) * | 2016-06-16 | 2020-02-26 | Hoyu Co., Ltd. | FISH ALLERGY ANTIGEN |
CN111629721A (zh) | 2017-12-06 | 2020-09-04 | 百乐吉公司 | 用于减少过敏反应的组合物和方法 |
EP4138909A1 (en) | 2020-04-19 | 2023-03-01 | Englmeier, Ludwig | Prophylaxis and treatment of coronavirus infection |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3598122A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US4286592A (en) | 1980-02-04 | 1981-09-01 | Alza Corporation | Therapeutic system for administering drugs to the skin |
US4314557A (en) | 1980-05-19 | 1982-02-09 | Alza Corporation | Dissolution controlled active agent dispenser |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
US4568343A (en) | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
US5352449A (en) | 1986-05-30 | 1994-10-04 | Cambridge Biotech Corporation | Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant |
US4948587A (en) | 1986-07-08 | 1990-08-14 | Massachusetts Institute Of Technology | Ultrasound enhancement of transbuccal drug delivery |
US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4780212A (en) | 1987-07-31 | 1988-10-25 | Massachusetts Institute Of Technology | Ultrasound enchancement of membrane permeability |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
GB2232892B (en) | 1988-02-23 | 1991-07-24 | John Mark Tucker | Occlusive body for administering a physiologically active substance |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
DK0382271T3 (da) | 1989-02-04 | 1995-05-01 | Akzo Nobel Nv | Tocoler som adjuvanser i vacciner |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
FR2649013B1 (fr) | 1989-07-03 | 1991-10-25 | Seppic Sa | Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable |
FR2649012B1 (fr) | 1989-07-03 | 1991-10-25 | Seppic Sa | Emulsions multiphasiques injectables |
US5464387A (en) | 1991-07-24 | 1995-11-07 | Alza Corporation | Transdermal delivery device |
US5273965A (en) | 1992-07-02 | 1993-12-28 | Cambridge Biotech Corporation | Methods for enhancing drug delivery with modified saponins |
TNSN93075A1 (fr) | 1992-07-08 | 1994-03-17 | Schering Corp | Utilisation de gm-csf comme adjuvant pour vaccin |
EP0892444B1 (en) | 1993-11-02 | 2004-04-21 | Matsushita Electric Industrial Co., Ltd | Semiconductor device comprising an aggregate of semiconductor micro-needles |
US5885211A (en) | 1993-11-15 | 1999-03-23 | Spectrix, Inc. | Microporation of human skin for monitoring the concentration of an analyte |
US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
US5458140A (en) | 1993-11-15 | 1995-10-17 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
DE9319879U1 (de) | 1993-12-23 | 1994-03-17 | Ems-Inventa AG, Zürich | Sequentiell Coextrudierte Kühlflüssigkeitsleitung |
US5457041A (en) | 1994-03-25 | 1995-10-10 | Science Applications International Corporation | Needle array and method of introducing biological substances into living cells using the needle array |
US5591139A (en) | 1994-06-06 | 1997-01-07 | The Regents Of The University Of California | IC-processed microneedles |
ATE420171T1 (de) | 1994-07-15 | 2009-01-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5618275A (en) | 1995-10-27 | 1997-04-08 | Sonex International Corporation | Ultrasonic method and apparatus for cosmetic and dermatological applications |
US5656016A (en) | 1996-03-18 | 1997-08-12 | Abbott Laboratories | Sonophoretic drug delivery system |
US5762943A (en) * | 1996-05-14 | 1998-06-09 | Ribi Immunochem Research, Inc. | Methods of treating type I hypersensitivity using monophosphoryl lipid A |
US7033598B2 (en) | 1996-11-19 | 2006-04-25 | Intrabrain International N.V. | Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
DE69815692T2 (de) | 1997-09-05 | 2004-04-29 | Glaxosmithkline Biologicals S.A. | Öl in wasser emulsionen mit saponinen |
GB2336310B (en) | 1998-04-14 | 2003-09-10 | Stowic Resources Ltd | Method of manufacturing transdermal patches |
US6322532B1 (en) | 1998-06-24 | 2001-11-27 | 3M Innovative Properties Company | Sonophoresis method and apparatus |
US20040006242A1 (en) * | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
US6685699B1 (en) | 1999-06-09 | 2004-02-03 | Spectrx, Inc. | Self-removing energy absorbing structure for thermal tissue ablation |
JP4162813B2 (ja) | 1999-10-28 | 2008-10-08 | 久光製薬株式会社 | イオントフォレーシス装置 |
US6974588B1 (en) | 1999-12-07 | 2005-12-13 | Elan Pharma International Limited | Transdermal patch for delivering volatile liquid drugs |
US6908453B2 (en) | 2002-01-15 | 2005-06-21 | 3M Innovative Properties Company | Microneedle devices and methods of manufacture |
US6676961B1 (en) | 2002-03-06 | 2004-01-13 | Automated Carrier Technologies, Inc. | Transdermal patch assembly |
US7018345B2 (en) | 2002-12-06 | 2006-03-28 | Hisamitsu Pharmaceutical Co., Inc. | Iontophoresis system |
SI2068918T1 (sl) * | 2006-09-26 | 2012-09-28 | Infectious Disease Res Inst | Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala |
US20090181078A1 (en) * | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
US8563523B2 (en) | 2007-09-07 | 2013-10-22 | University Of Georgia Research Foundation, Inc. | Synthetic lipid A derivative |
RU2732574C2 (ru) * | 2009-06-05 | 2020-09-21 | Инфекшес Дизиз Рисерч Инститьют | Синтетические глюкопиранозиллипидные адъюванты |
-
2015
- 2015-01-20 CN CN201580005108.2A patent/CN105960241A/zh active Pending
- 2015-01-20 BR BR112016016672A patent/BR112016016672A2/pt not_active Application Discontinuation
- 2015-01-20 CR CR20160369A patent/CR20160369A/es unknown
- 2015-01-20 EP EP15703170.9A patent/EP3096764A1/en not_active Withdrawn
- 2015-01-20 JP JP2016544662A patent/JP2017502977A/ja active Pending
- 2015-01-20 MX MX2016009464A patent/MX2016009464A/es unknown
- 2015-01-20 SG SG11201605883UA patent/SG11201605883UA/en unknown
- 2015-01-20 CA CA2935722A patent/CA2935722A1/en not_active Abandoned
- 2015-01-20 MA MA39228A patent/MA39228A1/fr unknown
- 2015-01-20 US US14/600,593 patent/US20160030459A1/en not_active Abandoned
- 2015-01-20 AU AU2015209575A patent/AU2015209575A1/en not_active Abandoned
- 2015-01-20 KR KR1020167018880A patent/KR20160105813A/ko not_active Application Discontinuation
- 2015-01-20 WO PCT/US2015/012003 patent/WO2015112485A1/en active Application Filing
- 2015-01-20 EA EA201691452A patent/EA201691452A1/ru unknown
- 2015-01-21 TW TW104101945A patent/TW201620524A/zh unknown
-
2016
- 2016-07-04 IL IL246587A patent/IL246587A0/en unknown
- 2016-07-20 CL CL2016001843A patent/CL2016001843A1/es unknown
- 2016-07-20 PH PH12016501434A patent/PH12016501434A1/en unknown
- 2016-12-21 HK HK16114518A patent/HK1225994A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA2935722A1 (en) | 2015-07-30 |
MA39228A1 (fr) | 2017-06-30 |
SG11201605883UA (en) | 2016-08-30 |
US20160030459A1 (en) | 2016-02-04 |
CN105960241A (zh) | 2016-09-21 |
AU2015209575A1 (en) | 2016-07-21 |
IL246587A0 (en) | 2016-08-31 |
KR20160105813A (ko) | 2016-09-07 |
BR112016016672A2 (pt) | 2017-08-08 |
MX2016009464A (es) | 2017-01-16 |
JP2017502977A (ja) | 2017-01-26 |
TW201620524A (zh) | 2016-06-16 |
EP3096764A1 (en) | 2016-11-30 |
PH12016501434A1 (en) | 2016-09-14 |
HK1225994A1 (zh) | 2017-09-22 |
WO2015112485A1 (en) | 2015-07-30 |
EA201691452A1 (ru) | 2016-12-30 |
CL2016001843A1 (es) | 2017-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018002012A1 (es) | Derivados de maitansinoide, conjugados de los mismos y métodos de uso. | |
CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
CL2018003754A1 (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo. | |
SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
CL2016002269A1 (es) | Moduladores alostéricos del núcleo proteico de la hepatitis b. | |
CL2017002422A1 (es) | Derivados de maitansinoide, conjugados de los mismos, y métodos de uso. | |
CL2016002735A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
ECSP17016797A (es) | Indazoles sustituidos con benzilo como inhibidores de bub1 | |
CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
DOP2016000109A (es) | Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas. | |
BR112016015706A2 (pt) | composto, uso do mesmo e composição farmacêutica | |
EA201692529A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
EA201691582A1 (ru) | Новые фармацевтические препараты | |
CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
CL2015002897A1 (es) | Inhibidores de bace1 | |
BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
EA201790787A1 (ru) | Снижение вязкости фармацевтических составов | |
DOP2016000336A (es) | Derivados de isoindolina para uso en el tratamiento de una infeccion viral | |
CL2016001937A1 (es) | Compuestos de benzopirano funcionalizados y uso de los mismos | |
CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
CO2018012180A2 (es) | Métodos de tratamiento para enfermedades colestásicas y fibróticas | |
BR112017009792A2 (pt) | anticorpos anti-pdgf-b e métodos de uso | |
DOP2016000170A (es) | Compuestos derivados de hidroxiformamida y usos del mismo |